OLUMIANT 2 MG
BARICITINIB : 2 MG · DIN 02480018 · ELI LILLY CANADA INC
Health Canada status: MARKETED
What is OLUMIANT?
OLUMIANT 2 MG contains BARICITINIB : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02480018, held by ELI LILLY CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Sep-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OLUMIANT used for?
RA: Moderate to severe rheumatoid arthritis in adults with inadequate response to DMARDs. AA: Severe alopecia areata in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02480018 |
|---|---|
| Brand name | OLUMIANT |
| Generic / active ingredient | BARICITINIB : 2 MG |
| Manufacturer | ELI LILLY CANADA INC |
| Strength | 2 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AF02 BARICITINIB |
| AHFS class | 90:24.12.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Sep-2018 |
| Original market date | 2018-09-27 00:00:00 |
How is it administered?
RA: 2 mg once daily with MTX (monotherapy if MTX intolerant). AA: 2 mg once daily; consider 4 mg for inadequate response or severe loss. Max 1 tablet/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (implied by standard Canadian monograph storage sections, though specific range text was truncated in snippet, section 11 is referenced).
How is it supplied?
Bottles of 30 or 90 tablets; blister packages of 14 or 28 tablets.
Contraindications
Hypersensitivity to baricitinib or any ingredient; pregnant women.
Warnings and precautions
Serious infections (TB, fungal, viral), malignancies (lymphoma, lung cancer), MACE (MI, stroke), and thrombosis (DVT, PE) which can be fatal. Risk of GI perforation.
What can be used instead?
Other Canadian products sharing ATC code L04AF02 BARICITINIB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OLUMIANT | 4 MG | TABLET | ELI LILLY CANADA INC | MARKETED | DIN 02544768 |
Who else supplies BARICITINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BARICITINIB appears in 37 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.